The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy; Zoltán Szlavik; James Murray; James Davidson; Ana Leticia Maragno; Gaëtane Le Toumelin-Braizat; Maïa Chanrion; Gemma L. Kelly; Jia Nan Gong; Donia M. Moujalled; Alain Bruno; Márton Csekei; Attila Paczal; Zoltán B. Szabo; Szabolcs Sipos; Gábor Radics; Agnes Proszenyak; Balázs Balint; Levente Ondi; Gábor Blasko; Giovanna Pomilio; Andrew H. Wei

doi:10.1038/nature19830

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

András Kotschy, Zoltán Szlavik, James Murray, James Davidson, Ana Leticia Maragno, Gaëtane Le Toumelin-Braizat, Maïa Chanrion, Gemma L. Kelly, Jia Nan Gong, Donia M. Moujalled, Alain Bruno, Márton Csekei, Attila Paczal, Zoltán B. Szabo, Szabolcs Sipos, Gábor Radics, Agnes Proszenyak, Balázs Balint, Levente Ondi, Gábor BlaskoGiovanna Pomilio, Andrew H. Wei

Australian Centre for Blood Diseases

Research output: Contribution to journal › Article › Research › peer-review

896 Citations (Scopus)

Abstract

Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.

Original language	English
Pages (from-to)	477-482
Number of pages	6
Journal	Nature
Volume	538
Issue number	7626
DOIs	https://doi.org/10.1038/nature19830
Publication status	Published - 2016

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Access to Document

10.1038/nature19830

Cite this

Kotschy, A., Szlavik, Z., Murray, J., Davidson, J., Maragno, A. L., Le Toumelin-Braizat, G., Chanrion, M., Kelly, G. L., Gong, J. N., Moujalled, D. M., Bruno, A., Csekei, M., Paczal, A., Szabo, Z. B., Sipos, S., Radics, G., Proszenyak, A., Balint, B., Ondi, L., ... Wei, A. H. (2016). The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models. Nature, 538(7626), 477-482. https://doi.org/10.1038/nature19830

@article{1ca3a07a4b1e41b58490b99b9f4b49f3,

title = "The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models",

abstract = "Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.",

author = "Andr{\'a}s Kotschy and Zolt{\'a}n Szlavik and James Murray and James Davidson and Maragno, \{Ana Leticia\} and \{Le Toumelin-Braizat\}, Ga{\"e}tane and Ma{\"i}a Chanrion and Kelly, \{Gemma L.\} and Gong, \{Jia Nan\} and Moujalled, \{Donia M.\} and Alain Bruno and M{\'a}rton Csekei and Attila Paczal and Szabo, \{Zolt{\'a}n B.\} and Szabolcs Sipos and G{\'a}bor Radics and Agnes Proszenyak and Bal{\'a}zs Balint and Levente Ondi and G{\'a}bor Blasko and Giovanna Pomilio and Wei, \{Andrew H.\}",

year = "2016",

doi = "10.1038/nature19830",

language = "English",

volume = "538",

pages = "477--482",

journal = "Nature",

issn = "0028-0836",

publisher = "Nature Publishing Group",

number = "7626",

}

Kotschy, A, Szlavik, Z, Murray, J, Davidson, J, Maragno, AL, Le Toumelin-Braizat, G, Chanrion, M, Kelly, GL, Gong, JN, Moujalled, DM, Bruno, A, Csekei, M, Paczal, A, Szabo, ZB, Sipos, S, Radics, G, Proszenyak, A, Balint, B, Ondi, L, Blasko, G, Pomilio, G & Wei, AH 2016, 'The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models', Nature, vol. 538, no. 7626, pp. 477-482. https://doi.org/10.1038/nature19830

TY - JOUR

T1 - The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

AU - Kotschy, András

AU - Szlavik, Zoltán

AU - Murray, James

AU - Davidson, James

AU - Maragno, Ana Leticia

AU - Le Toumelin-Braizat, Gaëtane

AU - Chanrion, Maïa

AU - Kelly, Gemma L.

AU - Gong, Jia Nan

AU - Moujalled, Donia M.

AU - Bruno, Alain

AU - Csekei, Márton

AU - Paczal, Attila

AU - Szabo, Zoltán B.

AU - Sipos, Szabolcs

AU - Radics, Gábor

AU - Proszenyak, Agnes

AU - Balint, Balázs

AU - Ondi, Levente

AU - Blasko, Gábor

AU - Pomilio, Giovanna

AU - Wei, Andrew H.

PY - 2016

Y1 - 2016

N2 - Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.

AB - Avoidance of apoptosis is critical for the development and sustained growth of tumours. The pro-survival protein myeloid cell leukemia 1 (MCL1) is overexpressed in many cancers, but the development of small molecules targeting this protein that are amenable for clinical testing has been challenging. Here we describe S63845, a small molecule that specifically binds with high affinity to the BH3-binding groove of MCL1. Our mechanistic studies demonstrate that S63845 potently kills MCL1-dependent cancer cells, including multiple myeloma, leukaemia and lymphoma cells, by activating the BAX/BAK-dependent mitochondrial apoptotic pathway. In vivo, S63845 shows potent anti-tumour activity with an acceptable safety margin as a single agent in several cancers. Moreover, MCL1 inhibition, either alone or in combination with other anti-cancer drugs, proved effective against several solid cancer-derived cell lines. These results point towards MCL1 as a target for the treatment of a wide range of tumours.

UR - https://www.scopus.com/pages/publications/84993984528

U2 - 10.1038/nature19830

DO - 10.1038/nature19830

M3 - Article

C2 - 27760111

AN - SCOPUS:84993984528

SN - 0028-0836

VL - 538

SP - 477

EP - 482

JO - Nature

JF - Nature

IS - 7626

ER -

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Abstract

UN SDGs

Access to Document

Other files and links

Apoptosis and stem cells in cancer development and therapy

Cite this

The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models

Abstract

UN SDGs

Access to Document

Other files and links

Projects

Apoptosis and stem cells in cancer development and therapy

Cite this